

**UTILITY PATENT APPLICATION
TRANSMITTAL**

(For new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No. **P50770X1C1**

First Named Inventor

Taylor



07/16/01



CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST-CLASS MAIL IN AN ENVELOPE ADDRESSED TO: ASSISTANT COMMISSIONER OF PATENTS, WASHINGTON, D.C. 20231, JULY 13, 2001

Kirk Baumester
AGENT/ATTORNEY FOR APPLICANT

7/13/2001

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

1. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to Deposit Account No. <u>19-2570</u>	7. <input checked="" type="checkbox"/> The Title of the Invention: MONOCLONAL ANTIBODIES WITH REDUCED IMMUNOGENICITY
<input checked="" type="checkbox"/> General Authorization to charge any and all fees under 37 CFR 1.16 or 1.17, including petitions for extensions of time, relating to this application. (37 CFR 1.136(a)(3)) <i>(Submit an original, and a duplicate for fee processing)</i>	8. <input checked="" type="checkbox"/> Nucleotide and/or Amino Acid Sequence Submission <ul style="list-style-type: none"> a. <input type="checkbox"/> Computer Readable Copy b. <input checked="" type="checkbox"/> Paper Copy (identical to computer copy) c. <input type="checkbox"/> Statement verifying identity of above copies d. <input checked="" type="checkbox"/> Use the identical computer-readable form filed in Application No. <u>09/300,970</u>, filed <u>April 28, 1999</u> as the computer-readable form for the instant application. (37 CFR 1.821(e))
2. <input checked="" type="checkbox"/> The total fee is calculated as shown below: Basic Filing fee \$710.00 Total Claims 19 - 20 = 0 x \$18 \$.00 Independent Claims 3 - 3 = 0 x \$80 \$.00 <input type="checkbox"/> Multiple Dependent Claim present. \$270 TOTAL FILING FEE \$710.00	9. <input type="checkbox"/> ACCOMPANYING APPLICATION PARTS <ul style="list-style-type: none"> a. <input type="checkbox"/> Information Disclosure Statement (IDS) b. <input checked="" type="checkbox"/> PTO-1449 c. <input type="checkbox"/> Copies of all IDS Citations
<input type="checkbox"/> Cancel in this application original claims <u>20</u> to <u>31</u> of the prior application before calculating the filing fee.	10. <input type="checkbox"/> Assignment Papers (cover sheet & document(s))
<input checked="" type="checkbox"/> Charge <u>\$710.00</u> to the above indicated Deposit Account.	11. <input checked="" type="checkbox"/> Prior Application is Assigned to: SmithKline Beecham Corporation <i>(for continuation/divisional with Box 17a completed)</i>
3a. <input checked="" type="checkbox"/> Specification excluding Drawings [Total Pages] <u>113</u>	12. <input type="checkbox"/> Preliminary Amendment [Total Pages]
3b. <input type="checkbox"/> Abstract on a separate sheet [Total Pages]	13. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) <i>(Should be specifically itemized)</i>
4. <input checked="" type="checkbox"/> Drawing(s) (35 USC 113) [Total Sheets] <u>6</u>	14. <input type="checkbox"/> Certified Copy of Priority Document(s) <i>(if foreign priority is claimed)</i>
5. <input checked="" type="checkbox"/> Declaration and Power of Attorney [Total Pages] <u>3</u> <ul style="list-style-type: none"> a. <input type="checkbox"/> Newly executed (original or copy) b. <input checked="" type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) <i>(for continuation/divisional with Box 17a completed)</i> c. <input type="checkbox"/> Unsigned Declaration <i>[Note Box 6 below]</i> <ul style="list-style-type: none"> i. <input type="checkbox"/> DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b). 	15. <input checked="" type="checkbox"/> Transfer all references cited by Applicants or by the Examiner from the parent Application Serial No. <u>09/300,970</u> filed <u>April 28, 1999</u> . A PTO-1449 listing the references is enclosed.
6. <input checked="" type="checkbox"/> Incorporation By Reference (<i>useable if Box 5b is checked</i>) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 5b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.	16. <input type="checkbox"/> Other: _____
17. <input checked="" type="checkbox"/> Priority Information, <i>check appropriate box and supply the requisite information</i>	
a. The accompanying application is a <input checked="" type="checkbox"/> Continuation <input type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-part (CIP) of prior application Serial No: <u>09/300,970</u> filed <u>April 28, 1999</u> .	
b. <input checked="" type="checkbox"/> Benefit is claimed under Title 35, United States Code, Section 119(e) of the following Provisional Applications: <u>Application No. 60/083,367 filed April 28, 1998.</u>	
c. <input checked="" type="checkbox"/> Please amend the specification by inserting before the first line the sentence: (37 CFR 1.78) This is a continuation of application Serial No. <u>09/300,970</u> filed <u>April 28, 1999</u> , which claims the benefit of U.S. Provisional Application No. <u>60/083,367</u> , filed <u>April 28, 1998</u> .	

18. CORRESPONDENCE ADDRESS

Address GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939

Telephone (610) 270-5096 Fax (610) 270-5090

19. RESPECTFULLY SUBMITTED,

Signature
Name

Kirk Baumester

Registration No. 33,833